Adalimumab for treating rheumatoid arthritis

Journal of Rheumatology

Volumn 33, Issue 6, 2006, Pages 1075-1081

  Navarro Sarabia, Federico ^a,b   Ariza Ariza, Rafael ^a   Hernández Cruz, Blanca ^a   Villanueva, Isidro ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b Rheumatology Service   (Spain)

Author keywords

Adalimumab; Cochrane systematic review; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ARTICLE; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; INFECTION; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH STATUS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33744766501     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Blumenauer B, Judd M, Wells G, et al. Infliximab for the treatment of rheumatoid arthritis. In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons Publishers.
2. Blumenauer B, Judd M, Cranney A, et al. Etanercept for the treatment of rheumatoid arthritis. In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons Publishers.
3. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis. Results of the Safety Trial of Adalimumab in Rheumatoid Arthritis. J Rheumatol 2003;30:2563-71.
4. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003;48:33-45.
5. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
6. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
7. Van Gestel AM, Prevoo ML, van t'Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism. Arthritis Rheum 1996;39:34-40.
8. Clarke M, Oxman AD, editors. The Cochrane Library, Issue 2, 2001.
9. Verhagen AP, Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic review developed by Delphi consensus. J Clin Epidemiol 1998;51:1235-41.
10. Jadad AR, Moore RA, Carroll D, et al. assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
11. Schultz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456-8.
12. Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Wells G, editors. Evidence-based rheumatology. London: BMJ Books; 2004.
13. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumour necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52 weeks trial. Arthritis Rheum 2004;50:1400-11.
14. Rau R, van Riel PLCM, van de Putte LBA, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol 2004;33:145-53.
15. van de Putte LBA, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E27) in DMARD refractory patients with rheumatoid arthritis: a 12 weeks, phase II study. Ann Rheum Dis 2003;62:1168-77.
16. van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.